Cabergoline : a review of its use in the treatment of Parkinson's disease.
Cabergoline is a synthetic ergoline dopamine agonist with a high affinity for dopamine D2 receptors and a long elimination half-life. This agent provides continuous dopaminergic stimulation with once-daily administration. Adjuvant oral cabergoline is usually well tolerated and effective in controlling symptoms in patients with advanced Parkinson's disease experiencing response fluctuations to long-term levodopa therapy. In patients with early Parkinson's disease, cabergoline (with or without levodopa) is well tolerated and effective in controlling disease symptoms, and may reduce the risk of developing drug-induced motor complications. Data from two pharmacoeconomic analyses suggest that cabergoline may be a cost-effective treatment option versus levodopa in patients with early Parkinson's disease, and highlight the need for further evaluation of the drug in this indication.
Curran
Monique P
MP
Adis International, Auckland, New Zealand. demail@adis.co.nz
Perry
Caroline M
CM
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D000077465:Cabergoline; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline